srpk1

SRPKIN-1 is a covalent and irreversible inhibitor of SRPK1/2 (IC50s: 35.6 and 98 nM, respectively).

SRPIN340 (SRPK inhibitor), a serine/arginine-rich protein kinase (SRPK)-specific inhibitor, is potent for SRPK1 (IC50 = 0.89 uM).

SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50: 5.9 nM).

Srpk1-IN-1 (compound 12) serves as a potent inhibitor of SRPK 1, demonstrating an IC 50 value of 0.3 nM [1].

CLK1/2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1/2-IN-3 induces nuclear speckle enlargement, which induces S6K pre-mRNA-selective splicing and subsequent inhibition of cell growth of multiple cancer cell types. cancer cell types cell growth.

SRPIN-803 is a selective dual SRPK1 and CK2 inhibitor.

GPS167 is a specific small-molecule splicing regulator and SRSF10 inhibitor that modulates BCLAF1 alternative splicing with an IC50 of 2 μM in human colorectal HCT116 cells, while also directly inhibiting CLK1, CLK2, and CLK4 but not SRPK1 or DYRK1A, positioning it as a mechanistically well-defined probe for studying spliceosome regulation and kinase-dependent RNA processing.

CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.

MSC-1186 is a potent and highly selective inhibitor targeting the pan-SRPK family, including SRPK1, SRPK2, and SRPK3, with IC 50 values of 2.7 nM, 81 nM, and 0.6 nM, respectively. Its specificity and effectiveness make it suitable for cancer research applications.

Antiangiogenic Agent 5 (Compound 17) exhibits potent anti-angiogenic activity by inhibiting SRPK 1 with an IC50 of 1.3 nM [1].